Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
8th grade Avg
|
|
New words:
abbreviated, Alaven, aminosalicylate, analyze, analyzed, ANDA, andC, Answer, apriso, Arcolab, arisen, auction, Australia, banker, bear, Bergamo, bioavailability, bioequivalence, black, box, boxed, budesonide, Catalent, CDC, citing, climate, collateral, collateralize, confirming, context, contrary, corroborated, Cosma, counter, Counterclaim, Court, crofelemer, Debtor, declaratory, denial, denied, deposit, designee, District, economy, EITF, eleven, embedded, ensuing, exceeding, expressly, family, foam, foregoing, fundamental, gastroesophageal, Glenmark, goal, guide, headcount, HIV, indenture, India, injury, interruption, IV, Jersey, junior, Kentucky, knowledge, lawsuit, lead, linked, Metozolv, mid, mitigation, mix, Mumbai, Nap, Napo, neuropsychiatric, nonrefundable, Obama, OSP, Paragraph, permission, Pharmatel, pivotal, political, preceding, predecessor, prevalent, principle, protocol, PTY, rank, redeem, redeemed, refinanced, repurchase, repurchased, retrospectively, saleable, scientifically, semiannually, South, spectrum, subordinated, substantive, suitable, suspended, Swindon, thereof, TID, timeline, treasury, trustee, unamortized, unenforceability, vigorously, waive, Winchester, Wuppertal, Zealand
Removed:
acceleration, achieved, area, assuming, Austria, belief, deliver, Denmark, diseased, Finland, forma, GAAP, Iceland, implemented, Ireland, light, Luxembourg, merger, model, negotiation, Norway, predominate, pro, ranging, Republic, Schwartz, Schwarz, site, stocking, studying, Sweden, thereon, training, UCB, unqualified, unvested, utility, volatility
Filing tables
Filing exhibits
- 10-K Annual report
- 10.64 Collaboration Agreement Between Napo Pharmaceuticals and Salix
- 10.65 Manufacturing and Supply Agreement Between Salix and Glenmark
- 21.1 Salix Pharmaceuticals, LTD. Subsidiaries
- 23.1 Consent of Pricewaterhousecoopers LLP
- 23.2 Consent of Ernst & Young LLP
- 31.1 Section 302 CEO Certification
- 31.2 Section 302 CFO Certification
- 32.1 Section 906 CEO Certification
- 32.2 Section 906 CFO Certification
Related press release
Salix Pharmaceuticals similar filings
Filing view
External links
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statement on Form S-3 (No. 333-110942) and Form S-8 (Nos. 333-126685, 333-126290, 333-116675, 333-96771, 333-63604, 333-61497, 333-135268, 333-47586 and 333-151658) of Salix Pharmaceuticals, Ltd. of our report dated March 11, 2009 relating to the financial statements, financial statement schedule and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Raleigh, North Carolina
March 11, 2009